Literature DB >> 20946579

Use of bisphosphonates in the management of postmenopausal osteoporosis.

Socrates E Papapoulos1.   

Abstract

Bisphosphonates are widely used in the treatment of postmenopausal osteoporosis. They decrease the rate of bone turnover, maintain or improve structural and material properties of bone, and increase bone mineral density and thereby decrease the risk of fractures. Available potent bisphosphonates can be given to patients by different dosing regimens that range from daily oral administration to yearly intravenous infusions. Controlled studies, extending to 10 years of continuous treatment, provide information about long-term efficacy and safety and can help in the planning of long-term treatment strategies. Selection of bisphosphonates for the treatment of individuals should be based on a careful review of efficacy data, a risk profile of the bisphosphonate, and values and preferences of the patient.
© 2010 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20946579     DOI: 10.1111/j.1749-6632.2010.05767.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  Long-Term Oral Bisphosphonate Compliance Focusing on Switching of Prescription Pattern.

Authors:  Sin Hyung Park; Soonchul Lee; Kyung Rae Ko; Sangcheol Lee; Seo Yoon Oh; Ki-Duk Kim
Journal:  Patient Prefer Adherence       Date:  2020-10-22       Impact factor: 2.711

Review 2.  Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.

Authors:  Andrea Giusti
Journal:  J Bone Miner Metab       Date:  2014-04-21       Impact factor: 2.626

3.  Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate.

Authors:  Esther M M van de Glind; Hanna C Willems; Saeid Eslami; Ameen Abu-Hanna; Willem F Lems; Lotty Hooft; Sophia E de Rooij; Dennis M Black; Barbara C van Munster
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

Review 4.  Treatment of complex regional pain syndrome type I with bisphosphonates.

Authors:  Andrea Giusti; Gerolamo Bianchi
Journal:  RMD Open       Date:  2015-08-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.